Prakt. lékáren. 2011; 7(6): 259-260

Hyperuricaemia and gout: basic facts

David Suchý

Oddělení klinické farmakologie FN Plzeň

Gout management has three key goals. Treatment of acute gout flares, prophylaxis against acute gout flares and long term treatment

of chronic gout. In last years, progress has been made in the better utilisation of old drugs and the development of new agents for the

treatment of gout. Febuxostat is a new non-purine selective xanthioxidase inhibitors that is more potent than allopurinol. Its efficacy was

confirmed in phase III trials, where significantly more febuxostat treated patients met the primary endpoint (serum urate < 360 μmol/l),

febuxostat was more effective in subset of patients with impaired renal function. Long term extension studies confirmed the efficacy

and tolerability of febuxostat. In patiens with target uric acid level, the incidence of gout flares fell continually and tophi resolved in

more than 50 % of patiens. The incidence of averse events during febuxostat treatment is probably similar to allopurinol. Febuxostat is

new, effective drug, which offers a new option for the long term treatment of gout.

Keywords: hyperuriacemia, gout, treatment, febuxostat

Published: December 1, 2011  Show citation